文献速递胸部介入CTPET

影像引导经皮微波热消融治疗原发性肺部恶性肿瘤后的局部控制、安全性与生存

Local control, safety, and survival following image-guided percutaneous microwave thermal ablation in primary lung malignancy.
PubMed 文献 · Clin Radiol · 2018-11-14

单中心研究纳入52例患者共61个不可切除原发性肺癌病灶,行CT引导高功率微波消融55次。局部肿瘤进展率10%,中位局部复发时间3个月;病灶>3 cm局部复发风险显著升高(OR约12倍),肿瘤>3 cm的癌症死亡风险比为4.37。气胸需引流为最严重并发症(22%),无术中死亡及30天死亡率0%。

要点

  • 病灶>3 cm时局部复发风险显著升高(OR约12倍,95%CI 1.84-75.14,p=0.009)。
  • 肿瘤>3 cm较≤3 cm的癌症死亡风险比为4.37(95%CI 1.45-13.17,p=0.009)。
  • 气胸需引流为最常见严重并发症,发生于22%(n=12)的患者。

核心结论

  • 微波消融治疗原发性肺部恶性肿瘤安全有效,其结局可能(may)与立体定向体部放疗相当。

研究设计与样本

  • 单中心研究,2010年7月至2016年6月纳入52例患者(平均年龄76.3岁,范围55-91岁)共61个不可切除原发性肺癌(平均直径23.8 mm,原文范围写作26-55 mm),行55次CT引导经皮高功率微波消融;肿瘤经活检诊断,或经PET摄取(平均SUVmax=10.51)及间隔增长诊断;统计采用Kaplan-Meier建模及Cox和逻辑回归。

诊断标准与关键数值

  • 局部肿瘤进展定义为6个病灶(10%),中位局部复发时间3个月(范围2-14个月)。
  • 病灶>3 cm时局部复发比值比约12倍(95%CI 1.84-75.14,p=0.009)。
  • 肿瘤>3 cm较≤3 cm的癌症死亡风险比HR 4.37(95%CI 1.45-13.17,p=0.009)。
  • 严重肺气肿预测未来需引流(OR 8.17,95%CI 1.62-41.37,p=0.01),预测FEV1<50%亦预测需引流(OR 5.14,95%CI 1.28-20.68,p=0.02),均校正年龄和性别。

临床应用与阅片要点

  • 气胸需引流为最严重并发症,发生于22%(n=12)的患者;中位住院时间1天,无术中死亡,30天消融后死亡率为0%。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

AIM: To determine local control, safety, and survival following percutaneous computed tomography (CT)-guided high-power microwave ablation (MWA) in the treatment of primary lung malignancy at a single institution.

MATERIAL AND METHODS: From July 2010 to June 2016, 52 patients (mean age 76.3 years, range 55-91 years) with 61 unresectable primary lung cancers of mean diameter 23.8 mm (range 26-55 mm) underwent MWA in 55 ablation sessions. Tumours were diagnosed at biopsy, or positron-emission tomography (PET) avidity (mean SUV max = 10.51) and interval growth. Statistical analysis was performed by Kaplan-Meier modelling and Cox and logistic regression.

RESULTS: Local tumour progression (LTP) was diagnosed in six lesions (10%). Median time to local recurrence was 3 months (range 2-14 months). There was a near 12-fold increased odds of local recurrence if the lesion size was >3 cm (95% confidence interval [CI]: 1.84-75.14; p=0.009). The median inpatient stay was 1 day, with no intra-procedural deaths and a 0% 30-day post-ablation mortality rate. Pneumothorax requiring drain was the most serious complication, occurring in 22% (n=12) of patients. Presence of severe emphysema and predicted forced expiratory volume in 1 second (FEV1) of <50% were found to predict future requirement of a drain (odds ratio [OR] 8.17, 95% CI: 1.62-41.37, p=0.01 and OR: 5.14, 95% CI: 1.28-20.68, p=0.02 respectively), when adjusted for age and gender. Tumour size >3 cm had a hazard ratio of 4.37 compared with tumour size ≤3 cm (95% CI: 1.45-13.17, p=0.009) of risk of cancer death at any time, by Cox regression.

CONCLUSION: MWA for primary lung malignancy is a safe and effective treatment for primary lung tumours with outcomes that may be comparable to stereotactic body radiation therapy.

来源:Clin Radiol,查看原文。版权归原作者所有。

引用

  1. Tsakok MT, Little MW, Hynes G, et al. Local control, safety, and survival following image-guided percutaneous microwave thermal ablation in primary lung malignancy. Clin Radiol. 2018. PMID: 30447997. doi:10.1016/j.crad.2018.09.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。